About flutiform

Indication

flutiform is licensed for asthma maintenance therapy for patients 12 years and older (low and medium strengths), adults (all dosage strengths). Not for acute symptom relief.

About Flutiform

New patients:

Not adequately controlled with inhaled corticosteroids and ‘as required’ inhaled short-acting β2-agonist

OR

Switch patients:

For patients already adequately controlled on both an inhaled corticosteroid and a long-acting β2-agonist. flutiform 50μg/5μg and 125μg/5μg is indicated in adults and adolescents aged 12 years and over.1

flutiform 250μg/10μg inhaler is indicated in adults only.1

1.0 Formulation

flutiform contains fluticasone propionate and formoterol fumarate.1

The steroid fluticasone propionate is contained in flutiform at the same doses as in Seretide® Evohaler®.2 The safety and efficacy data shows non-inferiority of fluticasone propionate/formoterol compared with fluticasone propionate/salmeterol.*3 

* Based on a 12 week open label study in asthma patients of 18 years and over using 50/5μg and 125/5μg only; primary endpoint, FEV1, P=0.007 demonstrating non-inferiority. flutiform is licensed for asthma maintenance therapy for patients 12 years and older (low and medium strengths), and adults (all strengths).

Mode of Action video

References

  1. Napp Pharmaceuticals Limited. flutiform® summary of product characteristics. (Last updated: August 2015). http://www.medicines.org.uk/emc/medicine/26954 [Accessed February 2018].
  2. GlaxoSmithKline. Seretide 50, 125, 250 Evohaler summary of product characteristics. (Last updated: April 2015). http://www.medicines.org.uk/emc/medicine/2914 [Accessed February 2018].
  3. Bodzenta-Lukaszyk A, Dymek A, et al. Fluticasone/formoterol combination therapy is as effective as fluticasone/salmeterol in the treatment of asthma, but has a more rapid onset of action: an open-label, randomized study. BMC Pulm Med 2011:11:28.